William Blair downgrades Apellis Pharmaceuticals (APLS) to a Hold
Apellis Pharmaceuticals received a Hold rating and price target from William Blair analyst Lachlan Hanbury Brown today.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Hanbury Brown is a 3-star analyst with an average return of 2.7% and a 27.54% success rate. Hanbury Brown covers the Healthcare sector, focusing on stocks such as LENZ Therapeutics, Apellis Pharmaceuticals, and ARS Pharmaceuticals.
In addition to William Blair, Apellis Pharmaceuticals also received a Hold from Needham’s Joseph Stringer in a report issued today. However, on March 17, Cantor Fitzgerald maintained a Buy rating on Apellis Pharmaceuticals (NASDAQ: APLS).
Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $199.91 million and a GAAP net loss of $58.95 million. In comparison, last year the company earned a revenue of $212.53 million and had a GAAP net loss of $36.35 million
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year. Last month, Mark Jeffrey DeLong, the Chief Business & Strat Officer of APLS sold 368.00 shares for a total of $8,151.20.
Read More on APLS:
